Sadelain, Michel

Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling

Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology

Pluripotent Stem Cells ResearchNeurogenesis and neuroplasticity mechanisms

Cited by 3,620

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,688

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,063

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature

CAR-T cell therapy researchCRISPR and Genetic Engineering

Cited by 1,831

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 1,432

Gene therapy comes of age

Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science

Virus-based gene therapy researchCRISPR and Genetic Engineering

Cited by 1,410

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,272

Senolytic CAR T cells reverse senescence-associated pathologies

Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature

Telomeres, Telomerase, and SenescenceCAR-T cell therapy research

Cited by 1,098

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 942

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 843

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 669

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 605

Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin

May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature

Virus-based gene therapy researchHemoglobinopathies and Related Disorders

Cited by 567

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 547

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 531

Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy

Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology

CAR-T cell therapy researchPluripotent Stem Cells Research

Cited by 473

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine

CAR-T cell therapy researchGut microbiota and health

Cited by 349

Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation

Papapetrou, E. P., Tomishima, M. J., Chambers, S. M., Mica, Y., Reed, E., Menon, J., Tabar, V., Mo, Q., Studer, L., & Sadelain, M. (2009) · Proceedings of the National Academy of Sciences

Pluripotent Stem Cells ResearchDevelopmental Biology and Gene Regulation

Cited by 286

HLA-independent T cell receptors for targeting tumors with low antigen density

Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 190

New cell sources for T cell engineering and adoptive immunotherapy

Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell

CAR-T cell therapy researchPluripotent Stem Cells Research

Cited by 179

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

Katsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., et al. (2021) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 131

Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function

Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., et al. (2024) · Cancer Discovery

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 95

Mass Cultured Human Fibroblasts Overexpressing hTERT Encounter a Growth Crisis Following an Extended Period of Proliferation

MacKenzie, K. L., Franco, S., May, C., Sadelain, M., & Moore, M. A. S. (2000) · Experimental Cell Research

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 92

Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects

Mansilla-Soto, J., Riviere, I., Boulad, F., & Sadelain, M. (2016) · Human Gene Therapy

Virus-based gene therapy researchHemoglobinopathies and Related Disorders

Cited by 83